Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04181476
Other study ID # 13223
Secondary ID
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date November 5, 2019
Est. completion date June 2022

Study information

Verified date January 2022
Source Henry Ford Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy of topical products in providing protection against the visible light and ultraviolet A1 (UVA1) part of sunlight. Ultraviolet radiation and visible light are both components of sunlight that reach the earth. It is important to test these topical products against visible light and UVA1 because our current sunscreens may not protect against these very well.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 12
Est. completion date June 2022
Est. primary completion date January 18, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patient age 18 and older - Patients Fitzpatrick skin phototype (SPT) III-IV with normal skin health - Patient able to understand requirements of the study and risks involved Exclusion Criteria: - A recent history of vitiligo, melasma, and other disorders of pigmentation with the exception of post inflammatory hyperpigmentation - A history of a relevant skin condition on any part of the patient's body (e.g. atopic dermatitis, eczema, vitiligo, sun burn, etc. - A known history of photodermatoses - A known history of photosensitivity disorders - A known history of melanoma or non-melanoma skin cancers

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Sunscreening Agents
Four different sunscreens

Locations

Country Name City State
United States Department of Dermatology, Henry Ford Medical Center, 3031 West Grand Boulevard, Detroit Michigan

Sponsors (2)

Lead Sponsor Collaborator
Henry Ford Health System L'Oreal

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Investigator's Global Assessment (IGA) Assesses erythema and pigmentation through study completion, an average of 1 week
Primary Change in Colorimetry Measures erythema and pigmentation through study completion, an average of 1 week
Primary Change in Diffuse Reflectance Spectroscopy Measures erythema and pigmentation through study completion, an average of 1 week
See also
  Status Clinical Trial Phase
Completed NCT05300542 - Efficacy Study of a Novel Skin Health Product to Reduce an UVB Induced Erythema N/A
Completed NCT05865431 - Singlet Oxygen Quantification After Skin Exposure to Ultraviolet A (UVA) Light N/A
Completed NCT05926791 - Photoprotective Effects of a SPF50+ Sunscreen on Skin Genotoxicity Induced by Repeated Chronic Outdoor Sun Exposure
Completed NCT05398237 - An Assessment of TLR4 and TOPK/PRPK Signaling in Sun Damaged Human Skin Acutely Exposed to Solar Simulated Light N/A
Completed NCT05162300 - Same-Day Combination of VI Peel and Botox for Correction of Sun Damage, Fine Lines and Wrinkles Phase 4
Completed NCT03110159 - DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients Phase 1/Phase 2
Completed NCT03006185 - Laser and Microdermabrasion Before Photodynamic Therapy for Actinic Keratoses in Field-cancerized Skin Phase 2
Enrolling by invitation NCT03007589 - Natural Sunlight Protection and Simulated Sunlight Protection Offered by Sunscreens and Fabrics N/A